Protein testing in patients with multiple myeloma : a review of clinical effectiveness and guidelines
Protein manifestations characteristic of multiple myeloma (MM) include increases of monoclonal (M)-protein concentrations (IgG, IgA, IgA, IgD), light chain concentrations (including kappa [ð] and lambda, abnormal ø2-microglobulin, serum albumin, creatinine, and hemoglobin levels, and findings of bone marrow plasma cells (of greater than or equal to 5%). Measurement of the protein manifestations produced by patients can be achieved by numerous methods. Traditional tests that measure M-proteins are the 24-hour urine collection test, urine protein electrophoresis (UPEP), serum protein electrophoresis (SPEP), and immunofixation electrophoresis (IFE). One newer test (developed in 2001) is the serum free light chain (sFLC) assay. The frequency with which to test using any of the tests along with the clinical utility of the newer tests remains in question. It is for this reason that a review of the clinical effectiveness, clinical utility, and guidelines of repeat testing for protein abnormalities in patients with MM was undertaken..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
09 January 2015 |
|---|---|
| Erschienen: |
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health ; 09 January 2015 |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Comparative Effectiveness Research |
|---|
| Anmerkungen: |
Title from PDF caption. - Includes bibliographical references. - Description based on version viewed May 22, 2015 |
|---|
| Umfang: |
1 online resource (1 PDF file (38 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773211897 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773211897 | ||
| 003 | DE-627 | ||
| 005 | 20230125174820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2015 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773211897 | ||
| 035 | |a (DE-599)KEP068682336 | ||
| 035 | |a (NCBI)9916531603406676 | ||
| 035 | |a (EBP)068682336 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Protein testing in patients with multiple myeloma |b a review of clinical effectiveness and guidelines |
| 264 | 1 | |a Ottawa (ON) |b Canadian Agency for Drugs and Technologies in Health |c 09 January 2015 | |
| 300 | |a 1 online resource (1 PDF file (38 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Rapid response report: summary with critical appraisal | |
| 500 | |a Title from PDF caption. - Includes bibliographical references. - Description based on version viewed May 22, 2015 | ||
| 520 | |a Protein manifestations characteristic of multiple myeloma (MM) include increases of monoclonal (M)-protein concentrations (IgG, IgA, IgA, IgD), light chain concentrations (including kappa [ð] and lambda, abnormal ø2-microglobulin, serum albumin, creatinine, and hemoglobin levels, and findings of bone marrow plasma cells (of greater than or equal to 5%). Measurement of the protein manifestations produced by patients can be achieved by numerous methods. Traditional tests that measure M-proteins are the 24-hour urine collection test, urine protein electrophoresis (UPEP), serum protein electrophoresis (SPEP), and immunofixation electrophoresis (IFE). One newer test (developed in 2001) is the serum free light chain (sFLC) assay. The frequency with which to test using any of the tests along with the clinical utility of the newer tests remains in question. It is for this reason that a review of the clinical effectiveness, clinical utility, and guidelines of repeat testing for protein abnormalities in patients with MM was undertaken. | ||
| 650 | 2 | |a Multiple Myeloma |0 https://id.nlm.nih.gov/mesh/D009101 | |
| 650 | 2 | |a Myeloma Proteins |0 https://id.nlm.nih.gov/mesh/D009194 | |
| 650 | 2 | |a Diagnostic Techniques and Procedures |0 https://id.nlm.nih.gov/mesh/D019937 | |
| 650 | 2 | |a Comparative Effectiveness Research |0 https://id.nlm.nih.gov/mesh/D057186 | |
| 655 | 2 | |a Review |0 https://id.nlm.nih.gov/mesh/D016454 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK269459/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994108357 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994034620 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999811234 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995698352 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987702192 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987785217 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK269459/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK269459/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK269459/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK269459/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK269459/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||